Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Acquisitions & Divestments (2017 - 2025)

Historic Change in Acquisitions & Divestments for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $19.1 million.

  • Aclaris Therapeutics' Change in Acquisitions & Divestments rose 1120.13% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.6 million, marking a year-over-year increase of 1948.94%. This contributed to the annual value of $86.1 million for FY2024, which is 5297.92% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $19.1 million for Q3 2025, which was up 1120.13% from $25.0 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $70.6 million for Q2 2023, and its period low was $8.0 million during Q4 2023.
  • Its 5-year average for Change in Acquisitions & Divestments is $31.0 million, with a median of $26.3 million in 2021.
  • In the last 5 years, Aclaris Therapeutics' Change in Acquisitions & Divestments soared by 37680.74% in 2021 and then plummeted by 8363.54% in 2023.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Change in Acquisitions & Divestments stood at $26.3 million in 2021, then soared by 85.56% to $48.8 million in 2022, then plummeted by 83.64% to $8.0 million in 2023, then skyrocketed by 119.17% to $17.5 million in 2024, then rose by 8.78% to $19.1 million in 2025.
  • Its last three reported values are $19.1 million in Q3 2025, $25.0 million for Q2 2025, and $30.0 million during Q1 2025.